GANX•Gain Therapeutics will present findings from rexaceract’s Phase 1b open-label extension study in Parkinson’s disease on Nov. 13, 2026, in Milan. The company will also present preclinical GT-04686 research at two November events.
Gain Therapeutics will present findings from rexaceract’s Phase 1b Parkinson’s disease open-label extension on Nov. 13, 2026, in Milan. Rexaceract is being evaluated for Parkinson’s disease with or without a GBA1 mutation.
Preclinical GT-04686 research will be featured at the Nov. 11-14 IAPRD congress, followed by a Nov. 17 presentation at Neuroscience 2026. The latter presentation describes reduced neuropathology and improved motor and non-motor function in a preclinical GBA1 Parkinson’s disease model.
